118 related articles for article (PubMed ID: 11333707)
1. [New drugs of year 2000: the challenges of the clinic and the manager].
Puigventós Latorre F
Med Clin (Barc); 2001 Mar; 116(12):465-8. PubMed ID: 11333707
[No Abstract] [Full Text] [Related]
2. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
3. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
[No Abstract] [Full Text] [Related]
4. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
5. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
Glasziou PP
Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
[TBL] [Abstract][Full Text] [Related]
6. FDA finalizes rules on accessing experimental drugs.
Traynor K
Am J Health Syst Pharm; 2009 Sep; 66(18):1596, 1599-600. PubMed ID: 19729557
[No Abstract] [Full Text] [Related]
7. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
8. Assessing the relative efficacy of new drugs: an emerging opportunity.
Eichler HG; Thomson A; Eichler I; Schneeweiss S
Nat Rev Drug Discov; 2015 Jul; 14(7):443-4. PubMed ID: 26129789
[TBL] [Abstract][Full Text] [Related]
9. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
Götte D
Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
[TBL] [Abstract][Full Text] [Related]
10. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
[No Abstract] [Full Text] [Related]
11. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
13. [Problems of clinical trials of new drugs as a basis of modern evidence-based medicine].
Moiseev VS
Ter Arkh; 2008; 80(12):5-10. PubMed ID: 19227898
[No Abstract] [Full Text] [Related]
14. [Rational introduction to new drugs requires both a health care and a community perspective].
Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergendahl GT; Wiking N
Lakartidningen; 2009 Jan 7-13; 106(1-2):52. PubMed ID: 19235325
[No Abstract] [Full Text] [Related]
15. [HTA-Perspective: Challenges in the early assessment of new oncological drugs].
Wild C; Nachtnebel A
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):129-35. PubMed ID: 23663907
[TBL] [Abstract][Full Text] [Related]
16. New chemical entities and their market penetration in Finland during the years 1996 through 2005.
Martikainen JE; Enlund H
Clin Ther; 2009 Mar; 31(3):668-76. PubMed ID: 19393857
[TBL] [Abstract][Full Text] [Related]
17. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
18. [The supply of experimental drugs in a clinical trial: who should pay?].
Lemaire F
Presse Med; 2015 Feb; 44(2):131-4. PubMed ID: 25596708
[No Abstract] [Full Text] [Related]
19. Helping the informed patient decide.
Lancet; 2005 Jun 18-24; 365(9477):2064. PubMed ID: 15968749
[No Abstract] [Full Text] [Related]
20. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.
Kalkman S; van Thiel GJ; Grobbee DE; Meinecke AK; Zuidgeest MG; van Delden JJ;
Trials; 2016 Aug; 17(1):419. PubMed ID: 27550379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
